Excited for TCT 2014? HCRI has been busy at work prepping for this year’s show! Come check out our newly expanded booth #2139 to chat with our staff and faculty on what we've been up to over the last year. This year's agenda will include case sessions from Dr. Laura Mauri, Dr. Robert Yeh, Dr. Don Cutlip, and others. We look forward to seeing everyone in DC!
A new study from HCRI highlights the importance of post market surveillance stent studies to depict safety signals. Postmarket surveillance of zotarolimus-eluting stents shows similar efficacy compared with premarket studies despite differences in patient populations but finds higher risk of myocardial infarction (MI), according to a paper published online June 9, 2014, in the American Journal of Cardiology.
New clinical trials of PRADAXA in different patient populations to add data to RE-VOLUTION®, BI’s extensive clinical trial program.
American Heart Association Meeting Coverage: Renal artery stenting was no more helpful than optimal medical therapy alone for moderately severe renal artery stenosis, the CORAL trial showed.